• AngioDynamics announced publication of DIRECT study results in The Oncologist, evaluating NanoKnife-based treatment in patients with Stage III pancreatic cancer.
• Treatment incorporating irreversible electroporation was associated with longer survival than standard care alone; the nonrandomized study cannot establish causation.
• A new Category I CPT code for open pancreatic irreversible electroporation takes effect January 1, 2027, standardizing procedure reporting.
• The code does not guarantee insurance coverage or payment, which vary by payer, plan and treatment setting.
• Prostate cancer remains the NanoKnife System’s commercial priority, with investment concentrated there despite the pancreatic cancer milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AngioDynamics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610210830BIZWIRE_USPR_____20261021_BW330748) on October 21, 2026, and is solely responsible for the information contained therein.